Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
109 Results for "
Osteosarcoma Inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (109)
109 Results for "Osteosarcoma Inhibitor" in MCE Product Catalog:
Cat. No.: HY-P11841
Target:
Research Areas:
Cat. No.: HY-W140346
CAS No.: 14915-37-8
Copper (II) pyrithione is a New Delhi metallo-β-lactamase 1 inhibitor. Copper (II) pyrithione inhibits New Delhi metallo-β-lactamase 1 via transmetallation of its zinc (II) cofactor with copper (II). Copper (II) pyrithione exerts cytotoxic effects on pancreatic cancer cells and osteosarcoma cells. Copper (II) pyrithione exhibits antibacterial activity against Gram-positive bacteria and some Gram-negative bacteria. Copper (II) pyrithione can synergistically enhance the activity of β-lactam antibiotics against β-lactam-resistant bacteria. Copper (II) pyrithione can be used in studies related to pancreatic cancer, osteosarcoma and bacterial infections .
Cat. No.: HY-P992055
Synonyms: AIIB2
Research Areas:
Anti-ITGB1 Antibody (AIIB2) is a monoclonal antibody targeting integrin-β1 (integrin-β1). Anti-ITGB1 Antibody blocks the binding of the ITGB1 subunit to type I collagen ligands, and abrogates the adhesion of cancer cells to type I collagen-coated surfaces. Anti-ITGB1 Antibody inhibits the proliferation and induces apoptosis of human osteosarcoma cells by activating caspase-3 and regulating apoptosis-related proteins. Anti-ITGB1 Antibody is applicable to research related to osteosarcoma and medulloblastoma .
Cat. No.: HY-182634
CAS No.: 714932-54-4
Target:
Research Areas:
NCGC00063279 is a reversible Werner Syndrome Helicase-Nuclease (WRN) helicase inhibitor with modest selectivity over BLM and FANCJ helicases, and does not inhibit WRN exonuclease activity at active concentrations. NCGC00063279 inhibits Hematopoietic Protein Tyrosine Phosphatase (HePTP) and reduces proliferation of cancer cells. NCGC00063279 can be used for the research of osteosarcoma .
Cat. No.: HY-189266
Target:
Research Areas:
PTP1B-IN-36 is a PTP1B inhibitor (IC50 0.70 μM) and a SHP2-E76K inhibitor (IC50 0.36 μM). PTP1B-IN-36 exhibits broad-spectrum inhibitory activity against PTP family enzymes, including TCPTP, SHP1-PTP, SHP2-PTP, and SHP1-WT. PTP1B-IN-36 shows anticancer activity against osteosarcoma. PTP1B-IN-36 can be used for research on osteosarcoma .
Cat. No.: HY-179650
CAS No.: 217798-45-3
Target:
Research Areas:
NSD2-PWWP1-IN-5 (Compound 13) is an effective NSD2-PWWP1 inhibitor with a Kd value of 78 nM. NSD2-PWWP1-IN-5 competitively blocks the recognition of H3K36me2 and DNA by NSD2-PWWP1, thereby weakening its binding ability to nucleosomes. NSD2-PWWP1-IN-5 inhibits the proliferation of U2OS osteosarcoma cells and induces cell cycle arrest and apoptosis. NSD2-PWWP1-IN-5 can be used for the study of osteosarcoma .
Cat. No.: HY-186167
CAS No.: 3110422-01-7
CDDO-biotin is an IKKβ inhibitor with cancer cell inhibitory activity. CDDO-biotin directly interacts with and oxidizes Cys-179 in the activation loop of IKKβ, forming an adduct with wild-type IKKβ. CDDO-biotin can be used in the research of myeloid leukemia, osteosarcoma, multiple myeloma, lung cancer, breast cancer and pancreatic cancer .
Cat. No.: HY-P11842
Target:
Research Areas:
Cat. No.: HY-174240
Target:
Research Areas:
Anticancer agent 274 (Compound 1) is a Sorafenib (HY-10201) analog. Anticancer agent 274 can inhibit the growth of tumor cells, with IC50 values of 0.034 μM and 0.042 μM against SaOS-2 and MNNG-HOS cells, respectively. Anticancer agent 274 has relatively low toxicity to normal cells and can be used in the research of tumors such as osteosarcoma .
Cat. No.: HY-19926A
CAS No.: 1778671-05-8
Synonyms: RG-7602 hydrochloride
Target:
Research Areas:
GDC-0425 hydrochloride (RG-7602 hydrochloride) is an orally active, highly selective ChK1 inhibitor. GDC-0425 hydrochloride abrogates cell cycle arrest and inhibits genomic repair. GDC-0425 hydrochloride potently suppresses Gemcitabine (HY-17026)-induced pCDK1/2 expression. GDC-0425 hydrochloride can be used in research related to osteosarcoma, ovarian cancer, basal (triple-negative) breast cancer, and colorectal cancer .
Cat. No.: HY-N9684
CAS No.: 39941-51-0
Cat. No.: HY-134901R
CAS No.: 2229025-70-9
Research Areas:
WM-3835 (Standard) is the analytical standard of WM-3835 (HY-134901). This product is intended for research and analytical applications. WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice .
Cat. No.: HY-179370
EEF1A2-IN-1 is a potent and covalen EEF1A2 inhibitor. EEF1A2-IN-1 exhibits selective antiproliferative activity against osteosarcoma (OS) cells. EEF1A2-IN-1 induces apoptosis by inhibiting EEF1A2 and downregulating the AKT signaling pathway. EEF1A2-IN-1 inhibits tumor growth in a xenograft mouse model. EEF1A2-IN-1 can be used for the research of OS .
Cat. No.: HY-184235
β-actin-IN-1 is a selective and covalent β-actin polymerization inhibitor. β-actin-IN-1 targets Cys272 of β-actin and shows selectivity over α-actin and γ-actin. β-actin-IN-1 inhibits β-actin polymerization and disrupts the actin cytoskeleton in cancer cells, leading to cell migration inhibition as well as cell death. β-actin-IN-1 can be used for the study of osteosarcoma .
Cat. No.: HY-176549A
CAS No.: 1704699-99-9
Research Areas:
IBR120 is a RAD51 inhibitor. IBR120 inhibits homologous recombination (HR) repair and attenuates RAD51-DNA interaction by binding to the hydrophobic pocket of the RAD51 core domain and disrupting RAD51 multimerization. IBR120 induces apoptotic cell death and inhibits the proliferation of a broad spectrum of cancer cell lines. IBR120 in combination with anticancer agents such as EGFR inhibitors and microtubule agents produces synergistic anti-proliferative effects. IBR120 can be used in research related to breast cancer, chronic myeloid leukemia, osteosarcoma, cervical cancer, and glioblastoma .
Cat. No.: HY-13777C
CAS No.: 131654-46-1
Synonyms: CGP 42446 disodium; CGP42446A disodium; ZOL 446 disodium
Zoledronate (CGP 42446) disodium is a potent bisphosphonate that effectively inhibits osteoclastogenesis, reducing bone turnover and stabilizing the bone matrix. Zoledronate disodium has demonstrated notable effectiveness in managing Paget's disease of bone by suppressing metabolic activity and alleviating bone pain. Zoledronate disodium is being investigated in the ongoing ZiPP trial for its potential to prevent disease progression in patients with Paget's disease. Zoledronate disodium also exhibits diverse anti-tumor effects in osteosarcoma, further highlighting its multifunctional therapeutic applications.
Cat. No.: HY-182539
CAS No.: 1202877-06-2
Target:
Research Areas:
Cat. No.: HY-187521
CAS No.: 102537-38-2
Target:
Research Areas:
MYCMI-7 hydrobromide is a potent and selective MYC/MYCN inhibitor, with a Kd of 4 μM for MYC and an IC50 of 10 μM for topoisomerase IIα (Topoisomerase IIα). MYCMI-7 hydrobromide binds directly to MYC, selectively inhibits the interactions of MYC:MAX and MYCN:MAX, reduces MYC-driven transcription levels, induces MYC/MYCN protein degradation, and blocks the binding of MYC to chromatin, thereby inducing tumor cell growth arrest, apoptosis and reducing cell viability, while only inducing G1 phase growth arrest in normal cells. MYCMI-7 hydrobromide can be used in research related to MYC-driven acute myeloid leukemia and breast cancer, MYCN-amplified neuroblastoma, glioblastoma, Burkitt's lymphoma, melanoma, colon cancer, osteosarcoma, cervical cancer and histiocytic lymphoma .
Cat. No.: HY-12238R
CAS No.: 1127442-82-3
Synonyms: endo-IWR 1 (Standard); IWR-1-endo (Standard)
Target:
Research Areas:
IWR-1 (Standard) is the analytical standard of IWR-1 (HY-12238). This product is intended for research and analytical applications. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .
Cat. No.: HY-137059
CAS No.: 1217503-60-0
Research Areas:
GO-Y078 is a curcumin (HY-N0005) analog. GO-Y078 activates p38/JNK1/2. GO-Y078 activates the MAPK pathway, Caspase 3/8/9, PARP, AP-1, DR5, and TP53, while inhibiting cIAP-1, XIAP, and NF-κB. GO-Y078 induces sub-G1/G2/M phase arrest and Apoptosis. GO-Y078 impairs angiogenesis. GO-Y078 can be used in research related to osteosarcoma, cervical cancer, oral squamous cell carcinoma, and peritoneal metastasis of gastric cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
